Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission.

Kana NagashimaShohei KikuchiSatoshi IyamaChisa FujitaAkari GotoHiroto HoriguchiMasayoshi Kobune

Published in: Clinical case reports (2020)

Brentuximab vedotin monotherapy for late-relapse CHL is a promising therapeutic with sustained CR benefit and avoiding potential toxicities caused by aPBSCT/HDT.

Keyphrases

hodgkin lymphoma
combination therapy
free survival
open label
disease activity
systemic lupus erythematosus